Literature DB >> 3220097

Pharmacokinetics of bolus intravenous and oral doses of L-carnitine in healthy subjects.

P Harper1, C E Elwin, G Cederblad.   

Abstract

The pharmacokinetics of single intravenous and oral doses of L-carnitine 2 and 6 g was studied in 6 healthy subjects on a low-carnitine diet. Carnitine was more rapidly eliminated from plasma after the 6 g dose. Comparing the doses, the t1/2 beta of the elimination phase (beta) was 6.5 h vs 3.9 h, the elimination constant 0.40 vs 0.50 h-1 and the plasma carnitine clearance was 5.4 vs 6.11.h-1 for the 2 g and 6 g doses, respectively, showing dose-related elimination. Saturable kinetics were not found. The apparent volumes of distribution after the two doses were not significantly different and were of the same order as the total body water. Urinary recoveries of the 2 g and 6 g doses were 70% and 82%, respectively, during the first 24 h. Following the oral doses, there was no significant difference between the areas under the plasma carnitine concentration-time curves. Urinary recovery was 8% and 4% for the 2 g and 6 g doses during the first 24 h. Oral bioavailability was 16% for the 2 g dose and 5% for the 6 g dose. The results suggest that the mucosal absorption of carnitine was already saturated by the 2 g dose.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3220097     DOI: 10.1007/bf00555510

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  20 in total

1.  A new urine preservative.

Authors:  L NAFTALIN; L R MITCHELL
Journal:  Clin Chim Acta       Date:  1958-03       Impact factor: 3.786

2.  Plasma carnitine and renal-carnitine clearance during pregnancy.

Authors:  G Cederblad; L Fåhraeus; K Lindgren
Journal:  Am J Clin Nutr       Date:  1986-09       Impact factor: 7.045

3.  A method for the determination of carnitine in the picomole range.

Authors:  G Cederblad; S Lindstedt
Journal:  Clin Chim Acta       Date:  1972-03       Impact factor: 3.786

4.  In vivo studies of intestinal carnitine absorption in rats.

Authors:  H Gudjonsson; B U Li; A L Shug; W A Olsen
Journal:  Gastroenterology       Date:  1985-06       Impact factor: 22.682

5.  Fat metabolism following an intravenous bolus dose of a fat emulsion and carnitine.

Authors:  G Cederblad
Journal:  Clin Physiol       Date:  1984-04

6.  Studies of carnitine metabolism in relation to intestinal absorption.

Authors:  H Gudjonsson; B U Li; A L Shug; W A Olsen
Journal:  Am J Physiol       Date:  1985-03

7.  Carnitine metabolism and inborn errors.

Authors:  A G Engel; C J Rebouche
Journal:  J Inherit Metab Dis       Date:  1984       Impact factor: 4.982

8.  Absorption of D- and L-carnitine by the intestine and kidney tubule in the rat.

Authors:  C J Gross; L M Henderson
Journal:  Biochim Biophys Acta       Date:  1984-05-16

Review 9.  Carnitine--metabolism and functions.

Authors:  J Bremer
Journal:  Physiol Rev       Date:  1983-10       Impact factor: 37.312

10.  Catabolic pathways for high-dosed L(-)- or D(+)-carnitine in germ-free rats?

Authors:  H Seim; J Schulze; E Strack
Journal:  Biol Chem Hoppe Seyler       Date:  1985-11
View more
  14 in total

1.  Case files of the Children's Hospital of Michigan Regional Poison Control Center: the use of carnitine for the management of acute valproic acid toxicity.

Authors:  Abhishek Katiyar; Cynthia Aaron
Journal:  J Med Toxicol       Date:  2007-09

2.  Biochemical Monitoring and Management During Pregnancy in Patients with Isovaleric Acidaemia is Helpful to Prevent Metabolic Decompensation.

Authors:  D D J Habets; N C Schaper; H Rogozinski; F J van Spronsen; M van Rijn; J Bierau; J A Bakker
Journal:  JIMD Rep       Date:  2011-09-27

Review 3.  Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects.

Authors:  Stephanie E Reuter; Allan M Evans
Journal:  Clin Pharmacokinet       Date:  2012-09-01       Impact factor: 6.447

4.  Enhanced bioavailability of L-carnitine after painless intradermal delivery vs. oral administration in rats.

Authors:  Suohui Zhang; Guangjiong Qin; Yan Wu; Yunhua Gao; Yuqin Qiu; Fang Li; Bai Xu
Journal:  Pharm Res       Date:  2010-04-13       Impact factor: 4.200

5.  L -Carnitine and the recovery from exhaustive endurance exercise: a randomised, double-blind, placebo-controlled trial.

Authors:  Christoph Stuessi; Pierre Hofer; Christian Meier; Urs Boutellier
Journal:  Eur J Appl Physiol       Date:  2005-09-29       Impact factor: 3.078

6.  Pharmacokinetics of propionyl-L-carnitine in humans: evidence for saturable tubular reabsorption.

Authors:  S Pace; A Longo; S Toon; P Rolan; A M Evans
Journal:  Br J Clin Pharmacol       Date:  2000-11       Impact factor: 4.335

7.  Screening for drugs potentially interfering with MCT8-mediated T3 transport in vitro identifies dexamethasone and some commonly used drugs as inhibitors of MCT8 activity.

Authors:  C Di Cosmo; G De Marco; P Agretti; E Ferrarini; A Dimida; P Falcetta; S Benvenga; P Vitti; M Tonacchera
Journal:  J Endocrinol Invest       Date:  2021-11-30       Impact factor: 4.256

8.  Protein ingestion acutely inhibits insulin-stimulated muscle carnitine uptake in healthy young men.

Authors:  Chris E Shannon; Aline V Nixon; Paul L Greenhaff; Francis B Stephens
Journal:  Am J Clin Nutr       Date:  2015-12-16       Impact factor: 7.045

9.  A pharmacokinetic model for L-carnitine in patients receiving haemodialysis.

Authors:  Gianfranco Fornasini; Richard N Upton; Allan M Evans
Journal:  Br J Clin Pharmacol       Date:  2007-05-15       Impact factor: 4.335

Review 10.  Pharmacokinetics of L-carnitine.

Authors:  Allan M Evans; Gianfranco Fornasini
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.